Personalized medicine

BullFrog AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo

Retrieved on: 
Tuesday, April 9, 2024
Organization, Conference, Drug discovery, COVID-19, Patient, Research, Artificial intelligence, Classification, Personalized medicine, Medicine, Quantum, Bullfrog, Machine learning, CSO

The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.

Key Points: 
  • The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.
  • Chittenden's presentation will explain how quantum methods have been used to decipher complex disease patterns, including analysis of multi-omics cancer data and classification of severe COVID-19 patients.
  • "The research I will highlight during my presentation is a testament to the synergies between quantum computing and machine learning, offering novel solutions to longstanding challenges in biomedical sciences."
  • The Quantum Computing Symposium is a premier event for professionals in the pharmaceutical industry, highlighting the revolutionary role of quantum technologies across various sectors, including drug discovery and supply chain management.

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

Retrieved on: 
Friday, April 5, 2024
Head, Algorithm, Immunotherapy, University, Neoplasm, PM, Vaccine, Analysis, Navigation, Mutation, Thermo Fisher Scientific, Cancer, Unprecedented, Glioblastoma, Result, Risk, Research, Tumor microenvironment, Antibody, Security (finance), Personalized medicine, PST, Proteomics, AACR, Pancreatic cancer, Ultrahigh, Conversation, Annual general meeting, AQUA, Lung cancer, University of Queensland, MIT, Titan Mare Explorer, Medical imaging

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10.

Key Points: 
  • MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10.
  • Industry-leading capabilities of the company’s spatial biology platforms will be presented during Akoya’s Spotlight Theater, titled “Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unprecedented Scale” on Monday, April 8 at 3 PM (PST).
  • Akoya Biosciences will demonstrate new uses of its PhenoCode Signature Panels for accelerating discovery and validation of spatial biomarkers using the PhenoImager HT 2.0 platform.
  • PhenoImager HT 2.0: Features targeted PhenoCode Signature Panels and onboard spectral unmixing, simplifying biomarker development and validation workflows for large scale studies.

American Oncology Network Announces Attendance and Participation at Leading Community Oncology Conference

Retrieved on: 
Thursday, March 28, 2024
Community, AON, CSSBB, Growth, Doctor of Pharmacy, Health, Partnership, Education, Patient, Knowledge, Cancer, COA, Hope, Matter, Personalized medicine, Community Oncology Alliance, MD, Privacy, Competition, MBA, Confidentiality, Pharmacy, Physician, Medicine, Pharmaceutical industry

FORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) announced its attendance and panel participation at the annual Community Oncology Alliance (COA) conference from April 4 to April 5 in Orlando, Florida, to further its mission of closing the cancer care gap and ensuring the viability of community oncology.

Key Points: 
  • FORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) announced its attendance and panel participation at the annual Community Oncology Alliance (COA) conference from April 4 to April 5 in Orlando, Florida, to further its mission of closing the cancer care gap and ensuring the viability of community oncology.
  • Since its inception, AON has provided administrative support and access to critical offerings such as the in-house pharmacy and laboratory services to independent oncology medical practices.
  • The conference brings together today’s healthcare and community oncology leaders for two days of education and networking.
  • We understand the future of healthcare is a collective effort, and the conference provides a platform to foster unity and the exchange of information.

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Retrieved on: 
Monday, March 18, 2024
EEG, U.S. FDA, Schizophrenia, Deficit spending, Data analysis, Memory, Alzheimer's disease, Central nervous system, Part, Delusion, Patient, CNS, ERP, Biomarker, Doctor of Philosophy, Parkinson's disease, Quality of life, Personalized medicine, Life, Trial of the century, Positive, Rett syndrome, Hallucination, PANSS, Therapy, SIGMAR1, DSM-IV codes, FDA, Pharmaceutical industry

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.

Key Points: 
  • “Initiating our Phase 2 trial of ANAVEX®3-71 in schizophrenia ahead of schedule is a testament to the hard work and dedication of our clinical study team,” stated Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
  • “Schizophrenia is a challenging disorder that can impair social and occupational functions and overall quality of life for the nearly 24 million people affected worldwide.
  • The placebo-controlled Phase 2, two-part, in-patient trial, ANAVEX®3-71-SZ-001 ( NCT06245213 ), will investigate the effects of ANAVEX®3-71 in patients with schizophrenia.
  • In addition to the electrophysiological biomarkers, Anavex is applying novel neuroinflammatory, metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX®3-71’s novel, dual mechanism of action.

Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board

Retrieved on: 
Tuesday, April 2, 2024
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Principal, Harvard Medical School, Education, DSM-IV codes, Associate, Nanoparticle, Patient, Biomedicine, RNA, Flagship Pioneering, Columbia University, AI, Faculty, Personalized medicine, Panasonic Executive Partner, Infection, Hospital, Division, Therapy, Medical director, Genomics, Nursing

Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors.

Key Points: 
  • Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors.
  • Dr. Chung currently serves as Chief of the Department of Pediatrics of Boston Children’s Hospital, sits on the faculty at Harvard Medical School, and is President of the Children’s Hospital Pediatric Associates.
  • Dr. Chung brings to Sail’s board more than 20 years of experience as a clinical and molecular geneticist, as well as biotech operational experience.
  • “I’m thrilled to contribute to Sail’s mission to create breakthroughs for patients with new types of RNA therapeutics and to join Sail’s distinguished Board of Directors,” said Dr. Chung.

Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, Genetics, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Exosome, EV, Plasma, ACE, Serum, Patient, RNA, DNA, Cancer, Personalized medicine, MD, Fluid mechanics, Doctor of Philosophy, AACR, Genomics, Prognosis, Biology, Centrifuge, Pharmaceutical industry

Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.
  • ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.
  • “Research has shown that exosomes carry important information about human health, but studying them has proven challenging,” said Paul R. Billings, MD, Ph.D., CEO and Chairman of Biological Dynamics.
  • Biological Dynamics will showcase ExoVerita Pro in Booth #4340 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., April 5-10.

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
Monday, March 25, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AbbVie, Ulcerative colitis, Growth, I&I, Cell, ACG, Patient, ABBV, UC, Journal, Biomarker, NIMML, Acquisition, LANCL2, IPO, SLE, Personalized medicine, Volunteering, A.I, IBD, Medicine, Rheumatoid arthritis, Epithelium, DRS, Invention, Therapy, NLRX1, Work, Pharmaceutical industry

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

Northwell Health’s Feinstein Institutes for Medical Research establishes first Professor in Women’s Health Research, boosting national movement to close gender gaps

Retrieved on: 
Tuesday, March 19, 2024
Research, Philanthropy, Oncology, Consumer, Hospitals, Fund Raising, Foundation, Science, Surgery, Women, Nursing, Health, Hospital, RN, Growth, Celebration, Health equity, Physician, Doctor of Philosophy, Barack Obama, Personalized medicine, Life, Medicine, Woman, North Shore University Hospital, Credit, Glen Cove Hospital, Katz, Medical research, Multimedia, FAAN, Feinstein, SHE, Impossible

Thanks to a generous endowment from women’s health advocates and philanthropists Iris and Saul Katz, Northwell Health and its home of medical research, the Feinstein Institutes for Medical Research , have established the Iris and Saul Katz Professor in Women’s Health Research in response to a national movement aimed at addressing the health care disparities facing women.

Key Points: 
  • Thanks to a generous endowment from women’s health advocates and philanthropists Iris and Saul Katz, Northwell Health and its home of medical research, the Feinstein Institutes for Medical Research , have established the Iris and Saul Katz Professor in Women’s Health Research in response to a national movement aimed at addressing the health care disparities facing women.
  • “While women’s health is now recognized as a national priority, Northwell has been addressing this issue for more than 15 years by creating solutions to close health gaps through the Katz Institute for Women’s Health , a network of more than 750 dedicated women’s health experts,” said Stacey E. Rosen, MD , executive director of the Katz Institute for Women’s Health, senior vice president of women’s health at Northwell and the Partners Council Professor of Women’s Health.
  • With more than 25 years of experience at North Shore University Hospital (NSUH) in Manhasset, she specializes in health equity, precision medicine and community-engaged research.
  • Cohn is highly regarded as a nurse-scientist and a champion for women’s health and medical research,” said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes and the Karches Family Distinguished Chair in Medical Research.

DNAnexus to Showcase the Power of High-Value Multi-Omics Data at the Precision Medicine in IBD Summit

Retrieved on: 
Monday, March 18, 2024
Hardware, Health Technology, Data Management, Technology, Nanotechnology, Pharmaceutical, General Health, Professional Services, Genetics, Biotechnology, Science, Software, Data Analytics, Internet, Research, Health, Cloud, Drug discovery, Tissue, RNA, Acquisition, Personalized medicine, IBD, Medicine, Inflammatory bowel disease, CLIA, Ecosystem, Ovation, Whole genome sequencing, Privacy, Pharmaceutical industry

The company is hosting a luncheon presentation that will focus on its collaboration with Ovation , an omics data company committed to accelerating the development of precision medicine, to help streamline large-scale omics data analysis.

Key Points: 
  • The company is hosting a luncheon presentation that will focus on its collaboration with Ovation , an omics data company committed to accelerating the development of precision medicine, to help streamline large-scale omics data analysis.
  • DNAnexus’ collaboration is initially focused on Ovation’s inflammatory bowel disease omics data, which includes whole genome sequencing and RNA sequencing on normal and diseased tissues linked to longitudinal clinical data.
  • Ovation’s omics data is derived from its extensive biobank of more than 1.6 million consented samples.
  • The secure and scalable DNAnexus Precision Health Data Cloud helps researchers manage, analyze, and collaborate on the complex multimodal data.

Yunkang Announces 2023 Annual Results, Revenue Reaches RMB892 Million

Retrieved on: 
Monday, March 25, 2024
Diagnosis, University, Sun, Personalized medicine, Specialization, Infection, Genetics, ESG, Accounting, Patient, DSM-IV codes, Research, Hospital, Fudan University, Stock exchange, Policy, Marie Cassidy, AI, Cancer, Laboratory, Medicine, City, Social, Neoplasm, Pathology, Intellectual property, League, Nanchang University, Medical device

HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2023 (the "Reporting Period"). In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million. The Group's routine testing business achieved a healthy and steady year-on-year growth of 26.9% during the Reporting Period. Due to enhanced operational and management capabilities and improved cost control, the overall gross profit margin remained stable at 36.5%. The Group further improved its operational and management capabilities and strengthened its cash flow management, resulting in a significant improvement in net cash generated from operating activities as compared with last year. As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million. The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023. 

Key Points: 
  • In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million.
  • As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million.
  • The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023.
  • During the Reporting Period, the Group's investment in R&D amounted to RMB55.3 million, which increased as a percentage of operating revenue to 6.2% for the year ended December 31, 2023.